All In Biotech

NDA 208794 · Tersera

Xermelo

Telotristat Etiprate · Oral

NovelPriority reviewOrphan

Last checked: Nov 20, 2026Latest source record: Sep 26, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Feb 28, 2017

Approved uses

1

Original approval plus efficacy supplements

Registered trials

25

5 Phase 3, 0 recruiting

FAERS reports

5,748

2,025 serious, 411 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 6, 2026.

Xermelo is indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. Xermelo is a tryptophan hydroxylase inhibitor indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. ( 1 )

Mechanism: Telotristat, the active metabolite of telotristat ethyl, is an inhibitor of tryptophan hydroxylase, which mediates the rate limiting step in serotonin biosynthesis. The in vitro inhibitory potency of telotristat towards tryptophan hydroxylase is 29 times higher than that of telotristat ethyl. Serotonin plays a role in mediating secretion, motility, inflammation, and sensation of the gastrointestinal tract, and is over-produced in patients with carcinoid syndrome. Through inhibition of tryptophan hydroxylase, telotristat and telotristat ethyl reduce the production of peripheral serotonin, and...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 28, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
1 products under this application
  • XERMELO · TELOTRISTAT ETIPRATE EQ 250MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Telotristat Etiprate" as an intervention, any sponsor and status, largest first.

All 25 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • diarrhoea841
  • nausea630
  • constipation606
  • off label use521
  • abdominal pain519
  • fatigue419
  • flatulence398
  • flushing353
  • death340
  • headache328
  • drug ineffective322
  • malaise255

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20131
20171,264
20181,722
20191,188
2020812
2021377
2022111
202396
202465
202557
202655

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xermelo (Telotristat Etiprate)

2024 spending

$24.2M

Beneficiaries

419

2,551 claims

Per beneficiary

$57,710

$113.23 per unit

View as table
YearSpending
2020$0
2021$0
2022$12,401,503
2023$18,340,851
2024$24,180,481

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4 on PubMed

Sponsor: Tersera

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.